The association between APOE alleles and ARIA, a known adverse reaction in Alzheimer’s disease patients treated with anti-amyloid monoclonal antibodies, has led to the inclusion of APOE genotyping among conventional pharmacogenetic tests. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.